RedHill Biopharma Ltd. (RDHL)
RedHill Biopharma Statistics
Share Statistics
RedHill Biopharma has 4.42K shares outstanding. The number of shares has increased by -96% in one year.
| Shares Outstanding | 4.42K |
| Shares Change (YoY) | -96% |
| Shares Change (QoQ) | -0.03% |
| Owned by Institutions (%) | 0.01% |
| Shares Floating | 4.4K |
| Failed to Deliver (FTD) Shares | 2.49K |
| FTD / Avg. Volume | 1.11% |
Short Selling Information
The latest short interest is 29.97K, so 2.34% of the outstanding shares have been sold short.
| Short Interest | 29.97K |
| Short % of Shares Out | 2.34% |
| Short % of Float | 0.09% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.01 and the forward PE ratio is null. RedHill Biopharma's PEG ratio is 0.
| PE Ratio | -0.01 |
| Forward PE | n/a |
| PS Ratio | 0.01 |
| Forward PS | 0 |
| PB Ratio | -0.02 |
| P/FCF Ratio | -0.01 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for RedHill Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.54, with a Debt / Equity ratio of -0.08.
| Current Ratio | 0.54 |
| Quick Ratio | 0.37 |
| Debt / Equity | -0.08 |
| Debt / EBITDA | -0.05 |
| Debt / FCF | -0.04 |
| Interest Coverage | -265.69 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $229.8K |
| Profits Per Employee | $-236.23K |
| Employee Count | 35 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 0.87 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -77.76% in the last 52 weeks. The beta is 4.43, so RedHill Biopharma's price volatility has been higher than the market average.
| Beta | 4.43 |
| 52-Week Price Change | -77.76% |
| 50-Day Moving Average | 3.06 |
| 200-Day Moving Average | 6.93 |
| Relative Strength Index (RSI) | 45.52 |
| Average Volume (20 Days) | 224.9K |
Income Statement
In the last 12 months, RedHill Biopharma had revenue of 8.04M and earned -8.27M in profits. Earnings per share was -512.
| Revenue | 8.04M |
| Gross Profit | 4.85M |
| Operating Income | -14.61M |
| Net Income | -8.27M |
| EBITDA | -7.59M |
| EBIT | -8.21M |
| Earnings Per Share (EPS) | -512 |
Balance Sheet
The company has 4.62M in cash and 356K in debt, giving a net cash position of 4.26M.
| Cash & Cash Equivalents | 4.62M |
| Total Debt | 356K |
| Net Cash | 4.26M |
| Retained Earnings | -414.8M |
| Total Assets | 18.04M |
| Working Capital | -10.31M |
Cash Flow
In the last 12 months, operating cash flow was -9.37M and capital expenditures -9K, giving a free cash flow of -9.38M.
| Operating Cash Flow | -9.37M |
| Capital Expenditures | -9K |
| Free Cash Flow | -9.38M |
| FCF Per Share | -1.45 |
Margins
Gross margin is 60.31%, with operating and profit margins of -181.69% and -102.8%.
| Gross Margin | 60.31% |
| Operating Margin | -181.69% |
| Pretax Margin | -102.8% |
| Profit Margin | -102.8% |
| EBITDA Margin | -94.42% |
| EBIT Margin | -181.69% |
| FCF Margin | -116.6% |
Dividends & Yields
RDHL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for RDHL.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Aug 20, 2024. It was a backward split with a ratio of 1:25.
| Last Split Date | Aug 20, 2024 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -22.36 |
| Piotroski F-Score | 2 |